Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist

Executive Summary

IND application filed for daptomycin for bacteremia and skin and soft tissue infections Jan. 1, CEO Scott Rocklage, PhD, reported Jan. 12. The company has completed a Phase II trial in skin and soft tissue infections, and is currently conducting Phase II studies for the bacteremia indication. Cubist expects to file NDAs for both indications by the end of 2000. FDA has said that it will designate the product for a "fast track" review
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033470

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel